29 related articles for article (PubMed ID: 38448368)
1. PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma.
Jin W; Wang G; Dong M; Wang X
Eur J Med Res; 2024 Mar; 29(1):177. PubMed ID: 38494503
[TBL] [Abstract][Full Text] [Related]
2. Fanconi Anemia Complementary Group A (FANCA) Facilitates the Occurrence and Progression of Liver Hepatocellular Carcinoma.
Huang FD; Zhong YP; Sun GY; Xu QJ; Xing ZY; Chen KH; Liao LS; Dong MY
Dig Dis Sci; 2024 Mar; 69(3):1035-1054. PubMed ID: 38282187
[TBL] [Abstract][Full Text] [Related]
3. Exploring the role of CDCA4 in liver hepatocellular carcinoma using bioinformatics analysis and experiments.
Liang C; Long K; Zheng W; Zhong R; Li Z; Zhu S; Gu S; Zhu C; Yang Y
Medicine (Baltimore); 2024 May; 103(18):e38028. PubMed ID: 38701314
[TBL] [Abstract][Full Text] [Related]
4. YBX1 as a prognostic biomarker and potential therapeutic target in hepatocellular carcinoma: A comprehensive investigation through bioinformatics analysis and in vitro study.
Li Z; Lu W; Yin F; Huang A
Transl Oncol; 2024 Apr; 45():101965. PubMed ID: 38688048
[TBL] [Abstract][Full Text] [Related]
5. Construction of a Cancer Stem Cell related Histone Acetylation Regulatory Genes Prognostic Model for Hepatocellular Carcinoma via Bioinformatics Analysis: Implications for Tumor Chemotherapy and Immunity.
Dai Q; Zhu J; Yang J; Zhang CY; Yang WJ; Pan BS; Yang XR; Guo W; Wang BL
Curr Stem Cell Res Ther; 2024 Mar; ():. PubMed ID: 38561604
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value and potential mechanism of cellular senescence and tumor microenvironment in hepatocellular carcinoma: Insights from bulk transcriptomics and single-cell sequencing analysis.
Qu C; Wu Q; Lu J; Li F
Environ Toxicol; 2024 May; 39(5):2512-2527. PubMed ID: 38189188
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic significance and carcinogenic mechanism of pan-cancer gene POU5F1 in liver hepatocellular carcinoma.
He D; Zhang X; Tu J
Cancer Med; 2020 Dec; 9(23):8782-8800. PubMed ID: 32978904
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive pan-cancer analysis of YBX family reveals YBX2 as a potential biomarker in liver cancer.
Yuan Z; Li B; Liao W; Kang D; Deng X; Tang H; Xie J; Hu D; Chen A
Front Immunol; 2024; 15():1382520. PubMed ID: 38698857
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of PSME3: from pan-cancer analysis to experimental validation.
Dong C; Guo Y; Yang Y; Ge X
Front Immunol; 2024; 15():1295693. PubMed ID: 38312840
[TBL] [Abstract][Full Text] [Related]
10. The comprehensive roles of lncRNA FAM99A/FAM99B in hepatocellular carcinoma: Expressions, regulatory mechanisms and functional pathway analysis.
Jin H; Li Y; Qin S; Li Q; Mao Y; Zhao L
Life Sci; 2024 May; 349():122710. PubMed ID: 38740325
[TBL] [Abstract][Full Text] [Related]
11. In silico analysis of overall survival with YBX1 in male and female solid tumours.
Grimes DR; Rassamegevanon T; Marignol L
Sci Rep; 2024 Mar; 14(1):7218. PubMed ID: 38538658
[TBL] [Abstract][Full Text] [Related]
12. Integrated single-cell and spatial transcriptomic analysis reveals YBX1 drives immune regulation in GBM progression.
Ge Y; Weng H; Sun Y; Wu M
Heliyon; 2024 Apr; 10(8):e29451. PubMed ID: 38628755
[TBL] [Abstract][Full Text] [Related]
13. Thorough examination of the potential biological implications of the cuproptosis-related gene LIPT2 in the prognosis and immunotherapy in pan-cancer.
Luo M; Rehman A; Haque S; Izhar S; Perveen F; Haris M; Abdel-Maksoud MA; Saleh IA; Zomot N; Malik A; Alamri A; Kodous AS; Aufy M; Zaky MY; Zaeem M; Hameed Y; Li J
Am J Transl Res; 2024; 16(3):940-954. PubMed ID: 38586090
[TBL] [Abstract][Full Text] [Related]
14. Exploration of YBX1 role in the prognostic value and immune characteristics by single-cell and bulk sequencing analysis for liver hepatocellular carcinoma.
Zhang Q; Zhu B; Yang H; Li F; Qu Y; Lu L; Zhang Q
J Gene Med; 2024 Mar; 26(3):e3680. PubMed ID: 38448368
[TBL] [Abstract][Full Text] [Related]
15. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
[TBL] [Abstract][Full Text] [Related]
16. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development.
Liu Z; Zhao P
J Cell Mol Med; 2024 Apr; 28(8):e18230. PubMed ID: 38568083
[TBL] [Abstract][Full Text] [Related]
17. Integration of single-cell RNA-seq and bulk RNA-seq to construct liver hepatocellular carcinoma stem cell signatures to explore their impact on patient prognosis and treatment.
Liu L; Zhang M; Cui N; Liu W; Di G; Wang Y; Xi X; Li H; Shen Z; Gu M; Wang Z; Jiang S; Liu B
PLoS One; 2024; 19(4):e0298004. PubMed ID: 38635528
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
